Reviewing Xeris Pharmaceuticals Inc. (XERS)’s and Ionis Pharmaceuticals Inc. (NASDAQ:IONS)’s results

We will be comparing the differences between Xeris Pharmaceuticals Inc. (NASDAQ:XERS) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as far as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xeris Pharmaceuticals Inc. 2.45M 137.45 73.45M -2.41 0.00
Ionis Pharmaceuticals Inc. 752.47M 12.45 365.62M 0.51 137.95

Table 1 highlights Xeris Pharmaceuticals Inc. and Ionis Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Xeris Pharmaceuticals Inc. -2,997.96% 0% 0%
Ionis Pharmaceuticals Inc. 48.59% -31.1% -8.7%

Liquidity

The Current Ratio of Xeris Pharmaceuticals Inc. is 16.5 while its Quick Ratio stands at 16.5. The Current Ratio of rival Ionis Pharmaceuticals Inc. is 8 and its Quick Ratio is has 8. Xeris Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Ionis Pharmaceuticals Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Xeris Pharmaceuticals Inc. and Ionis Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Xeris Pharmaceuticals Inc. 0 0 0 0.00
Ionis Pharmaceuticals Inc. 0 2 1 2.33

Meanwhile, Ionis Pharmaceuticals Inc.’s consensus price target is $68.33, while its potential upside is 2.38%.

Insider and Institutional Ownership

Xeris Pharmaceuticals Inc. and Ionis Pharmaceuticals Inc. has shares held by institutional investors as follows: 48.6% and 89.1%. 2.4% are Xeris Pharmaceuticals Inc.’s share held by insiders. Insiders Comparatively, held 0.2% of Ionis Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xeris Pharmaceuticals Inc. 3.75% -24.35% -47.89% -59.92% 0% -38.24%
Ionis Pharmaceuticals Inc. 14.3% 21.53% 21.62% 52.61% 33.45% 30.39%

For the past year Xeris Pharmaceuticals Inc. has -38.24% weaker performance while Ionis Pharmaceuticals Inc. has 30.39% stronger performance.

Summary

Ionis Pharmaceuticals Inc. beats Xeris Pharmaceuticals Inc. on 8 of the 12 factors.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.